ClinicalTrials.gg
WithdrawnNCT05018871Updated Nov 19, 2026

Safety of Cultured Umbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP

A Phase 1 interventional study of Umbilical or placental derived mesenchymal stem cells in Cerebral Palsy, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Withdrawn at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Duplicate registration; study is registered and actively tracked under NCT05018819. No participants were enrolled under this record.
Updated Nov 19, 2026Now WithdrawnNow Recruiting+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 372 studies in Cerebral Palsy with a site in United States — 74 open to participants now, 102 under way, none of them phase 3. Cerebral Palsy · United States.

Enrollment
283rd of 296
0 · median 25
Started
2026
with 23 others
Phase 1
25 of 372
4 open now
Registered
237th of 372
by date

Among the 372 studies in Cerebral Palsy with a site in United States, this one is the 283rd largest by enrollment of the 296 interventional ones that give a count, is one of 24 that started in 2026, is one of 25 in phase 1, and was the 237th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

74 of the 372 studies in Cerebral Palsy with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 372 studies in Cerebral Palsy with a site in United States, or all of them as a file.
02

Study summary

This trial will study the safety and efficacy of intravenous infusion of cultured umbilical or placental derived mesenchymal stem cells for the treatment of Cerebral Palsy

Read the detailed description

Studies have shown that stem cell treatment is safe and efficacious for the treatment of Cerebral Palsy (CP). This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured umbilical or placental derived mesenchymal stem cells for the treatment of CP. Patients with CP will receive a single intravenous infusion of MSCs.

03

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • Cerebral Palsy
  • CP
  • stem cell treatment
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Cerebral Palsy

Exclusion criteria

Exclusion Criteria:

  • Active infection
  • Active cancer
  • Chronic multisystem organ failure
  • Pregnancy
  • Abnormalities on pre-treatment laboratory evaluation
  • Medical condition that would (based on the opinion of the investigator) compromise patient's safety
  • Previous organ transplant
  • Seizure disorder
  • to sulfur
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Single intravenous infusion of 100 million cells

    Biological: Umbilical or placental derived mesenchymal stem cells

Interventions

  • BiologicalUmbilical or placental derived mesenchymal stem cells

    Umbilical or placental derived mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. Safety (adverse events)

    Clinical monitoring of possible adverse events or complications

    Time frame: Four year follow-up

Secondary outcomes

  1. Efficacy: Gross Motor Function Measure (GMFM)

    It will be completed for each follow up point

    Time frame: Four year follow-up

07

Study locations

2 sites
08

References and documents

Publications

  • Alotaibi M, Long T, Kennedy E, Bavishi S. The efficacy of GMFM-88 and GMFM-66 to detect changes in gross motor function in children with cerebral palsy (CP): a literature review. Disabil Rehabil. 2014;36(8):617-27. doi: 10.3109/09638288.2013.805820. Epub 2013 Jun 26. PubMed 23802141 ↗
  • Ko J, Kim M. Reliability and responsiveness of the gross motor function measure-88 in children with cerebral palsy. Phys Ther. 2013 Mar;93(3):393-400. doi: 10.2522/ptj.20110374. Epub 2012 Nov 8. PubMed 23139425 ↗
  • Huang L, Zhang C, Gu J, Wu W, Shen Z, Zhou X, Lu H. A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy. Cell Transplant. 2018 Feb;27(2):325-334. doi: 10.1177/0963689717729379. PubMed 29637820 ↗
  • Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS, Jang SJ, Kim SH, Oh D, Kim MK, Kim SS, Kim M. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells. 2013 Mar;31(3):581-91. doi: 10.1002/stem.1304. PubMed 23281216 ↗
  • Liu X, Fu X, Dai G, Wang X, Zhang Z, Cheng H, Zheng P, An Y. Comparative analysis of curative effect of bone marrow mesenchymal stem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy. J Transl Med. 2017 Feb 24;15(1):48. doi: 10.1186/s12967-017-1149-0. PubMed 28235424 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2021
First posted
Aug 24, 2021
StartEst.
Dec 2026was Dec 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting→Withdrawn Duplicate registration; study is registered and actively tracked under NCT05018819. No participants were enrolled under this record.
changed Oct 16, 2026 · changed Nov 19, 2026
Sites
2 sites added, 1 site removed — first site in United States
Show 2 added (1 United States, 1 Greece)
  • Prodromos Stem Cell Institute · Naples, United States
  • Prodromos Stem Cell Institute · Athens, Greece
Show 1 removed
  • Mitera Hospital Athens Greece · Marousi, Greece
Oct 16, 2026
Start date
Dec 2025→Dec 2026
Oct 16, 2026
Enrollment
15 (estimated)→0 (actual)
Nov 19, 2026
Interventions
Changed autologous adipose derived mesenchymal stem cells→Umbilical or placental derived mesenchymal stem cells
Oct 16, 2026
Contact
Study contact now listed: added c•••@thepsci.com · •••6810. See the current contact
Oct 16, 2026
Title
Safety of Cultured Autologous Adult AdiposeUmbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP
Oct 16, 2026
Show all 2 updates
  1. Nov 19, 2026
    Recruiting→Withdrawn
    Why stopped Duplicate registration; study is registered and actively tracked under NCT05018819. No participants were enrolled under this record.
    Enrollment 15 (estimated)→0 (actual)
    + 3 other changes: verification date, contact details and site details
  2. Oct 16, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    2 sites added, 1 site removed — first site in United States
    Show 2 added (1 United States, 1 Greece)
    • Prodromos Stem Cell Institute · Naples, United States
    • Prodromos Stem Cell Institute · Athens, Greece
    Show 1 removed
    • Mitera Hospital Athens Greece · Marousi, Greece
    Start date Dec 2025→Dec 2026
    Interventions Changed autologous adipose derived mesenchymal stem cells→Umbilical or placental derived mesenchymal stem cells
    Contact Study contact now listed: added c•••@thepsci.com · •••6810. See the current contact
    Title Safety of Cultured Autologous Adult AdiposeUmbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05018871
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Dec 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion